Phase 3 Recruiting Network
This study is being done to answer the following question: can the chance of prostate cancer growing or spreading be lowered by adding a drug to the usual combination of drugs? This study would like to find out if this approach is better o…
Sponsor: Canadian Cancer Trials Group
NCT ID: NCT06592924
Sites in Pennsylvania: - Christiana Care Health System-Concord Health Center — Chadds Ford, Pennsylvania
- Geisinger Medical Center — Danville, Pennsylvania
- Geisinger Cancer Center Dickson City — Dickson City, Pennsylvania
- Geisinger Medical Center-Cancer Center Hazleton — Hazleton, Pennsylvania
- Geisinger Medical Oncology-Lewisburg — Lewisburg, Pennsylvania
Phase 3 Recruiting Network
This phase III trial tests two questions by two separate comparisons of therapies. The first question is whether enhanced therapy (apalutamide in combination with abiraterone + prednisone) added to standard of care (prostate radiation ther…
Sponsor: ECOG-ACRIN Cancer Research Group
NCT ID: NCT04423211
Sites in Pennsylvania: - UPMC Altoona — Altoona, Pennsylvania
- UPMC-Heritage Valley Health System Beaver — Beaver, Pennsylvania
- Crozer-Keystone Regional Cancer Center at Broomall — Broomall, Pennsylvania
- Carlisle Regional Cancer Center — Carlisle, Pennsylvania
- Delaware County Memorial Hospital — Drexel Hill, Pennsylvania
Phase 3 Recruiting Network
This phase III trial studies how well standard systemic therapy with or without definitive treatment (prostate removal surgery or radiation therapy) works in treating participants with prostate cancer that has spread to other places in the…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT03678025
Sites in Pennsylvania: - Chambersburg Hospital — Chambersburg, Pennsylvania
- Geisinger Medical Center — Danville, Pennsylvania
- Ephrata Cancer Center — Ephrata, Pennsylvania
- Adams Cancer Center — Gettysburg, Pennsylvania
- Sechler Family Cancer Center — Lebanon, Pennsylvania
Phase 3 Recruiting Academic/Other
This phase III trial tests whether high-dose vitamin D works in treating androgen-deprivation therapy (ADT)-induced bone loss in patients with prostate cancer who are undergoing androgen-deprivation therapy. Vitamins are substances that th…
Sponsor: University of Rochester
NCT ID: NCT05838716
Sites in Pennsylvania: - Geisinger Cancer Center Dickson City — Dickson City, Pennsylvania
- Community Medical Center — Scranton, Pennsylvania
- Geisinger Wyoming Valley/Henry Cancer Center — Wilkes-Barre, Pennsylvania
Phase 3 Recruiting Network
This study is being done to answer the following question: Is the strategy to give higher doses of radiotherapy treatment over a shorter period of time using special equipment and fewer treatments (also known as Stereotactic Body Radiation…
Sponsor: Canadian Cancer Trials Group
NCT ID: NCT06235697
Sites in Pennsylvania: - Saint Vincent Hospital — Erie, Pennsylvania
- Jefferson Hospital — Jefferson Hills, Pennsylvania
- Forbes Hospital — Monroeville, Pennsylvania
- Allegheny General Hospital — Pittsburgh, Pennsylvania
- West Penn Hospital — Pittsburgh, Pennsylvania
Phase 3 Recruiting Industry
The purpose of the study is to demonstrate superiority of Saruparib (AZD5305) relative to placebo added to a standard radiation therapy (RT) + androgen deprivation therapy (ADT) regimen by assessment of metastases-free survival in particip…
Sponsor: AstraZeneca
NCT ID: NCT06952803
Sites in Pennsylvania: - Research Site — Hershey, Pennsylvania
- Research Site — Lancaster, Pennsylvania
- Research Site — Pittsburgh, Pennsylvania
Phase 3 Recruiting Industry
The primary objective of this study is to compare overall survival (OS) in participants receiving xaluritamig plus abiraterone against investigator's choice (docetaxel, cabazitaxel, or abiraterone).
Sponsor: Amgen
NCT ID: NCT07213674
Sites in Pennsylvania: - University of Pittsburgh Medical Center — Pittsburgh, Pennsylvania
Phase 3 Recruiting Industry
The intention of the study is to demonstrate superiority of AZD2265 relative to standard of care treatments by assessment of radiographic progression-free survival (rPFS) and overall survival (OS) in participants with mCRPC.
Sponsor: AstraZeneca
NCT ID: NCT07611110
Sites in Pennsylvania: - Research Site — Pittsburgh, Pennsylvania
Phase 2, Phase 3 Recruiting Federal
This is a prospective, open-label, multi-center seamless phase II to phase III randomized clinical trial designed to compare SST with or without PET-directed local therapy in improving the castration-resistant prostate cancer-free survival…
Sponsor: VA Office of Research and Development
NCT ID: NCT04787744
Sites in Pennsylvania: - Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA — Philadelphia, Pennsylvania
Phase 3 Recruiting Industry
This is an open label, longitudinal Phase 3 study of prostate specific membrane antigen (PSMA) positron emission tomography (PET) combined with magnetic resonance imaging (MRI) compared to standard of care (SOC) for the detection of prosta…
Sponsor: Telix Pharmaceuticals (Innovations) Pty Limited
NCT ID: NCT07052214
Sites in Pennsylvania: - MidLantic Urology — Philadelphia, Pennsylvania
Phase 2 Recruiting NIH
This phase II trial studies how well cabozantinib works in combination with nivolumab and ipilimumab in treating patients with rare genitourinary (GU) tumors that has spread from where it first started (primary site) to other places in the…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT03866382
Sites in Pennsylvania: - Lehigh Valley Hospital-Cedar Crest — Allentown, Pennsylvania
- Lehigh Valley Hospital - Muhlenberg — Bethlehem, Pennsylvania
- Pocono Medical Center — East Stroudsburg, Pennsylvania
- UPMC Hillman Cancer Center Erie — Erie, Pennsylvania
- Saint Vincent Hospital — Erie, Pennsylvania
Phase 2 Recruiting Industry
The purpose of this study is to collect long term safety data in subjects who are continuing to derive clinical benefit from treatment with Enzalutamide from the subjects participation in an enzalutamide clinical study sponsored by Astella…
Sponsor: Astellas Pharma Global Development, Inc.
NCT ID: NCT02960022
Sites in Pennsylvania: - Site US10027 — Lancaster, Pennsylvania
- Site US10005 — Pittsburgh, Pennsylvania
Phase 1, Phase 2 Recruiting Industry
The goal of this clinical trial is to determine if FOG-001 is safe and effective in participants with locally advanced or metastatic solid tumors or in participants with familial adenomatous polyposis (FAP).
Sponsor: Parabilis Medicines, Inc.
NCT ID: NCT05919264
Sites in Pennsylvania: - University of Pennsylvania, Perelman School of Medicine — Philadelphia, Pennsylvania
- University of Pittsburgh Medical Center, Hillman Cancer Center — Pittsburgh, Pennsylvania
Phase 1, Phase 2 Recruiting Industry
The purpose of this open-label, first-in-human (FIH) trial is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of DZR123 (Tulmimetostat, CPI-0209), both as monotherapy and in comb…
Sponsor: Novartis Pharmaceuticals
NCT ID: NCT04104776
Sites in Pennsylvania: - Abramson Cancer Center of the University of Pennsylvania — Philadelphia, Pennsylvania
Phase 2 Recruiting Industry
This Phase II study aims to evaluate efficacy and safety of the combination of JSB462 (also known as luxdegalutamide) at 100 mg and 300 mg once a day (QD) doses + abiraterone compared with an androgen receptor pathway inhibitor (ARPI, abir…
Sponsor: Novartis Pharmaceuticals
NCT ID: NCT06991556
Sites in Pennsylvania: - MidLantic Urology — Bala-Cynwyd, Pennsylvania
- Fox Chase Cancer Center — Philadelphia, Pennsylvania
Phase 1, Phase 2 Recruiting Industry
This is a two-part, open-label, multicenter, dose escalation and dose expansion study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PDx), and anti- tumor activity of ETX-19477, a novel reversible s…
Sponsor: 858 Therapeutics, Inc.
NCT ID: NCT06395519
Sites in Pennsylvania: - Thomas Jefferson University, Sidney Kimmel Comprehensive Cancer Center — Philadelphia, Pennsylvania
Phase 1, Phase 2 Recruiting Academic/Other
The purpose of this study is to find out whether tinengotinib in combination with abiraterone acetate and prednisone or enzalutamide is a safe treatment that causes few or mild side effects in people with metastatic castration-resistant pr…
Sponsor: Memorial Sloan Kettering Cancer Center
NCT ID: NCT06457919
Sites in Pennsylvania: - Thomas Jefferson University Hospital — Philadelphia, Pennsylvania
Phase 2 Recruiting Academic/Other
The researchers are doing this study to find out whether tarlatamab is an effective treatment for Delta-like Protein 3 (DLL3)-positive prostate cancer that has spread to other parts of your body (metastasized) and has either come back afte…
Sponsor: Memorial Sloan Kettering Cancer Center
NCT ID: NCT07111507
Sites in Pennsylvania: - Thomas Jefferson University Hospital — Philadelphia, Pennsylvania
Phase 2 Recruiting Academic/Other
This research is being done to see if we can improve the outcome of prostate cancer patients who present with metastatic lesions at initial diagnosis.
Sponsor: University of Maryland, Baltimore
NCT ID: NCT05223803
Sites in Pennsylvania: - Sidney Kimmel Cancer Center at Jefferson Health — Philadelphia, Pennsylvania
- UPMC Hillman Cancer Center — Pittsburgh, Pennsylvania
Phase 2 Recruiting Academic/Other
This phase II trial studies how well prostate specific membrane antigen (PSMA) or fluciclovine positron emission tomography (PET)/computed tomography (CT) site-directed therapy works for treating patients with prostate cancer. PSMA or fluc…
Sponsor: University of Washington
NCT ID: NCT04175431
Sites in Pennsylvania: - University of Pittsburgh Cancer Institute (UPCI) — Pittsburgh, Pennsylvania
Phase 1 Recruiting Industry
TTX-080-001 is a Phase 1, open label, dose escalation and dose expansion clinical study to determine the safety, tolerability, and recommended Phase 2 dose of TTX-080 monotherapy (HLA-G inhibitor) and in combination with either pembrolizum…
Sponsor: Tizona Therapeutics, Inc
NCT ID: NCT04485013
Sites in Pennsylvania: - University of Pittsburgh Medical Center — Pittsburgh, Pennsylvania
Phase 1 Recruiting Industry
This study is a first-in-human, Phase 1, open-label, multicenter study to assess the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD), and the preliminary efficacy of JANX007 in adults with metastatic castration-resistant p…
Sponsor: Janux Therapeutics
NCT ID: NCT05519449
Sites in Pennsylvania: - Penn State Milton S. Hershey Medical Center — Hershey, Pennsylvania
- Thomas Jefferson University Honickman Center — Philadelphia, Pennsylvania
- UPMC Hillman Cancer Center — Pittsburgh, Pennsylvania
Phase 1 Recruiting Industry
Medicines that reduce the amount of testosterone in the body are commonly used to treat prostate cancer. PRL-02 depot is a potential treatment for men with advanced prostate cancer. It is given by an injection into the muscle. Men with adv…
Sponsor: Astellas Pharma Global Development, Inc.
NCT ID: NCT04729114
Sites in Pennsylvania: - MidLantic Urology — Bala-Cynwyd, Pennsylvania
Phase 1 Recruiting Industry
Phase 1 dose escalation and expansion study of CLSP-1025, a first-in-class HLA-A\*02:01 specific T cell engager (TCE) targeting solid tumors that harbor the p53 R175H mutation.
Sponsor: Clasp Therapeutics, Inc.
NCT ID: NCT06778863
Sites in Pennsylvania: - Thomas Jefferson University, Sidney Kimmel Cancer Center — Philadelphia, Pennsylvania
- Fox Chase Cancer Center — Philadelphia, Pennsylvania
Phase 1 Recruiting Industry
The purpose of this study is to establish the safety and preliminary antitumor activity of ORIC-944 as a single agent and in combinations with ARPIs in patients with metastatic prostate cancer.
Sponsor: ORIC Pharmaceuticals
NCT ID: NCT05413421
Sites in Pennsylvania: - MidLantic Urology — Bala-Cynwyd, Pennsylvania
- Keystone Urology Specialists — Lancaster, Pennsylvania